Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2354-2364

  Yi, Ping ^a   Rehmel, Jessica Fayer ^a   Cassidy, Kenneth ^a   Hadden, Chad ^a   Campanale, Kristina ^a   Patel, Nita ^a   Johnson, Jason ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CYTOCHROME P450 3A4; DRUG METABOLITE; EPOXIDE; ISOPROPYL N [7 CYANO 4 (2 PYRIDYLMETHYL) 2,3 DIHYDRO 1H CYCLOPENTA(B)INDOL 2 YL]CARBAMATE; LY 2452473; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ACIDITY; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; FECES; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; ISOTOPE LABELING; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHROMATOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ADULT; AREA UNDER CURVE; CARBAMATES; CYTOCHROME P-450 CYP3A; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANDROGEN; YOUNG ADULT;

EID: 84869132250     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047613     Document Type: Article

References (22)

1. Adam W, Ahrweiler M, Perters K, and Schmiedeskamp B (1994) Oxidation of N-acylindoles by dimethyldioxirane and singlet oxygen: substituent effects on thermally persistent indole epoxides and dioxetanes. J Org Chem 59:2733-2739.
2. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, et al. (2002) Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77:660-665.
3. Basaria S and Dobs AS (1999) Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 15:131-142.
4. Buvat J, Montorsi F, Cuzin B, Meuleman E, Yassin A, and Dean J (2009) From which serum testosterone level should we add testosterone therapy to men with erectile dysfunction not responding to PDE5 inhibitors alone? A double blind placebo controlled trial of testosterone gel addition to men not responding to tadalafil once a day alone. J Urol 181:488.
5. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, and Khosla S (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560.
6. Gao W and Dalton JT (2007) Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 12:241-248.
7. Gelfand MM and Wiita B (1997) Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 19:383-404; discussion 367-368.
8. Ghosal A, Gupta S, Ramanathan R, Yuan Y, Lu X, Su AD, Alvarez N, Zbaida S, Chowdhury SK, and Alton KB (2009) Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett 3:162-170.
9. Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, and Lu AY (2011) Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 36:1-16.
10. Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, and Ehlhardt WJ (2004) Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos 32:966-972.
11. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, and Finkelstein JS (2003) Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88:204-210.
12. Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP 3rd, Freiwald S, Zientek M, and Totah RA (2010) Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38:347-356.
13. Lee CA, Jones JP 3rd, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, and Totah RA (2012) Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos 40:943-951.
14. Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings SR, and Osteoporotic Fractures in Men Study Group (2006) Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 166:2124-2131.
15. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
16. Rosenthal BD, May NR, Metro MJ, Harkaway RC, and Ginsberg PC (2006) Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 67:571-574.
17. Schroeder ET, Terk M, and Sattler FR (2003) Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies. Am J Physiol Endocrinol Metab 285:E16-E24.
18. 14C-labelled insecticide carbaryl by non-transformed and human CYP1A1-, CYP1A2-, and CYP3A4-transgenic cell cultures of Nicotiana tabacum. Chem Biodivers 3:878-896.
19. Shabsigh R, Kaufman JM, Steidle C, and Padma-Nathan H (2004) Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172:658-663.
20. Sullivan ME, Keoghane SR, and Miller MA (2001) Vascular risk factors and erectile dysfunction. BJU Int 87:838-845.
21. Wolfson L, Judge J, Whipple R, and King M (1995) Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol A Biol Sci Med Sci 50:64-67.
22. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, and Cayen MN (1996) Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 51:165-172.